Wolverine Trading’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.26M | Buy |
119,900
+51,600
| +76% | +$920K | ﹤0.01% | 2064 |
|
|
2025
Q2 | $1.17M | Buy |
68,300
+45,300
| +197% | +$1.93M | ﹤0.01% | 2162 |
|
|
2025
Q1 | $1.62M | Sell |
23,000
-6,800
| -23% | -$716K | ﹤0.01% | 1799 |
|
|
2024
Q4 | $3.61M | Sell |
29,800
-4,200
| -12% | -$515K | ﹤0.01% | 1459 |
|
|
2024
Q3 | $4.23M | Sell |
34,000
-10,300
| -23% | -$1.42M | ﹤0.01% | 1155 |
|
|
2024
Q2 | $7M | Buy |
44,300
+17,000
| +62% | +$2.18M | 0.01% | 798 |
|
|
2024
Q1 | $3.53M | Sell |
27,300
-27,500
| -50% | -$3.37M | ﹤0.01% | 1225 |
|
|
2023
Q4 | $5.28M | Buy |
54,800
+2,000
| +4% | +$192K | 0.01% | 1057 |
|
|
2023
Q3 | $6.4M | Buy |
52,800
+23,700
| +81% | +$2.68M | 0.01% | 841 |
|
|
2023
Q2 | $3.27M | Sell |
29,100
-39,700
| -58% | -$5.12M | ﹤0.01% | 1172 |
|
|
2023
Q1 | $9.36M | Buy |
68,800
+41,900
| +156% | +$5.44M | 0.01% | 565 |
|
|
2022
Q4 | $3.49M | Buy |
26,900
+20,600
| +327% | +$2.39M | 0.01% | 1075 |
|
|
2022
Q3 | $691K | Sell |
6,300
-2,200
| -26% | -$222K | ﹤0.01% | 2304 |
|
|
2022
Q2 | $655K | Buy |
8,500
+900
| +12% | +$66.2K | ﹤0.01% | 2286 |
|
|
2022
Q1 | $597K | Sell |
7,600
-16,600
| -69% | -$1.27M | ﹤0.01% | 3014 |
|
|
2021
Q4 | $2.19M | Sell |
24,200
-1,300
| -5% | -$111K | ﹤0.01% | 1799 |
|
|
2021
Q3 | $2.26M | Buy |
25,500
+100
| +0.4% | +$7.7K | ﹤0.01% | 2024 |
|
|
2021
Q2 | $2M | Sell |
25,400
-28,600
| -53% | -$2.17M | ﹤0.01% | 1980 |
|
|
2021
Q1 | $3.95M | Sell |
54,000
-9,600
| -15% | -$886K | 0.01% | 1316 |
|
|
2020
Q4 | $10.9M | Buy |
63,600
+12,300
| +24% | +$1.82M | 0.02% | 637 |
|
|
2020
Q3 | $7.25M | Sell |
51,300
-23,500
| -31% | -$3.57M | 0.02% | 654 |
|
|
2020
Q2 | $12.2M | Sell |
74,800
-28,600
| -28% | -$3.89M | 0.03% | 393 |
|
|
2020
Q1 | $10.2M | Sell |
103,400
-18,600
| -15% | -$2.13M | 0.03% | 420 |
|
|
2019
Q4 | $15.7M | Buy |
+122,000
| New | +$12.3M | 0.04% | 470 |
|
|
2019
Q2 | – | Sell |
-144,700
| Closed | -$17.2M | – | 5090 |
|
|
2019
Q1 | $17.2M | Sell |
144,700
-13,000
| -8% | -$1.67M | 0.05% | 308 |
|
|
2018
Q4 | $17M | Sell |
157,700
-30,500
| -16% | -$3.81M | 0.05% | 302 |
|
|
2018
Q3 | $30.4M | Buy |
188,200
+21,900
| +13% | +$2.99M | 0.07% | 188 |
|
|
2018
Q2 | $12.3M | Hold |
166,300
| – | – | 0.03% | 409 |
|
|
2018
Q1 | $12.3M | Sell |
166,300
-57,600
| -26% | -$3.84M | 0.03% | 409 |
|
|
2017
Q4 | $12.5M | Sell |
223,900
-43,500
| -16% | -$2.3M | 0.05% | 411 |
|
|
2017
Q3 | $12.1M | Buy |
267,400
+83,600
| +45% | +$3.34M | 0.05% | 361 |
|
|
2017
Q2 | $6.13M | Sell |
183,800
-13,000
| -7% | -$423K | 0.03% | 574 |
|
|
2017
Q1 | $5.71M | Sell |
196,800
-8,300
| -4% | -$257K | 0.03% | 584 |
|
|
2016
Q4 | $5.63M | Sell |
205,100
-74,000
| -27% | -$2.97M | 0.03% | 661 |
|
|
2016
Q3 | $17M | Sell |
279,100
-8,700
| -3% | -$263K | 0.08% | 270 |
|
|
2016
Q2 | $5.37M | Buy |
+287,800
| New | +$5.33M | 0.03% | 585 |
|
Other funds holding SRPT
EAM
Wolverine Trading's SRPT Position: Q3 2025 in Review
Wolverine Trading increased its Sarepta Therapeutics (SRPT) stake by 20% in Q3 2025, buying an estimated $50.3K and bringing the position to 16,719 shares worth $315K. The position accounts for ﹤0.01% of the portfolio, ranked #4310.
Wolverine Trading first reported a position in SRPT in Q3 2016 and has held it in 29 quarters since. The position peaked at $8.79M in Q3 2018. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.
- Wolverine Trading held 16,719 shares of Sarepta Therapeutics worth $315K as of Q3 2025.
- Wolverine Trading bought 2,819 Sarepta Therapeutics shares in Q3 2025, an estimated $50.3K.
- Sarepta Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #4310 holding.
- Wolverine Trading first reported a position in Sarepta Therapeutics in Q3 2016 and has held it in 29 quarters since.
- Wolverine Trading's Sarepta Therapeutics position peaked at $8.79M in Q3 2018.
- 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.